Aptose Provides Update on APTO-253 Program | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 20 December, 2021 by The TZ Newswire Staff

Aptose Provides Update on APTO-253 Program

— Clinical development of the MYC repressor APTO-253 will be discontinued —

— Company will focus on advancing kinome inhibitor pipeline —

See also
- Next Article The American City Where People Are Most Likely to Have a White Christmas
- Previous Article Clarkson (LON:CKN) Stock Rating Reaffirmed by JPMorgan Chase & Co.
Editorial Calender

December 2021

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Nov Jan »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar